A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: mistake (35), fault (22), slip (31)

Finance and Performance Reports 2024-25 Month 7 October 2024

Description
Report to the Trust Board of Directors, 29 November 2024 Title: Finance Report 2024-25 Month 7 Sponsor: Ian Howard, Chief
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Finance-and-Performance-Reports-2024-25-Month-7-October-2024.pdf

Cyclophosphamide Docetaxel Epirubicin (100) Fluorouracil Pertuzumab Trastuzumab FE100CT-HP

Description
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOCETAXEL-EPIRUBICIN (100)- FLUOROURACILPERTUZUMAB-TRASTUZUMAB (FE100CT-HP) Regimen • Breast Cancer – Cyclophosphamide-Docetaxel-Epirubicin (100)-FluorouracilPertuzumab-Trastuzumab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Cyclophosphamide-Docetaxel-Epirubicin-100-Fluorouracil-Pertuzumab-Trastuzumab-FE100CT-HP.pdf

Carboplatin Paclitaxel EC Pembrolizumab Neoadjuvant Ver1.0

Description
Chemotherapy Protocol BREAST CANCER PEMBROLIZUMAB WITH CARBOPLATIN/PACLITAXEL AND EC NEOADJUVANT BREAST CANCER FOLLOWED BY ADJUVANT PEMBROLIZUMAB Regimen • Breast-Pembrolizumab with
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-Paclitaxel-EC-Pembrolizumab-Neoadjuvant.pdf

Finance and Performance Reports 2024-25 Month 5 August 2024

Description
Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose: Finance Report 2024-25 Month 5 N
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Finance-and-Performance-Reports-2024-25-Month-5-August-2024.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description
Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexamethasone (40)-Pomalidomide Indication • Isatuximab is indicated where; - the patient has
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

Glofitamab-Obinutuzumab

Description
Chemotherapy Protocol LYMPHOMA GLOFITAMAB-OBINUTUZUMAB Regimen • Lymphoma-Glofitamab-Obinutuzumab Indication • Treatment of adult patients with relapsed or refractory diffuse large B
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Glofitamab-Obinutuzumab.pdf

Carfilzomib Dexamethasone(40) Lenalidomide

Description
Chemotherapy Protocol MYELOMA Carfilzomib -Lenalidomide -Dexamethasone Regimen • Myeloma – Carfilzomib-Lenalidomide-Dexamethasone Indication • Carfilzomib in combination with lenalidomide and dexamethasone is an
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Carfilzomib-Dexamethasone40-Lenalidomide.pdf

Carboplatin(AUC6)-Paclitaxel-Pembrolizumab

Description
Chemotherapy Protocol LUNG CANCER CARBOPLATIN (AUC6)-PACLITAXEL-PEMBROLIZUMAB Regimen • Lung-Carboplatin (AUC6)-Paclitaxel-Pembrolizumab Indication - The patient has a histologically- or
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CarboplatinAUC6-Paclitaxel-Pembrolizumab.pdf

Carboplatin-Pembrolizumab-Pemetrexed

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN (AUC 5)-PEMBROLIZUMAB-PEMETREXED Regimen • NSCLC – Carboplatin (AUC5)-Pembrolizumab-Pemetrexed Indication • Pembrolizumab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Carboplatin-Pembrolizumab-Pemetrexed.pdf

PV-CHP Cyclophosphamide-doxorubicin-polatuzumab vedotin -prednisolone

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-POLATUZUMAB VEDOTIN-PREDNISOLONE- RITUXIMAB Regimen • Lymphoma – Cyclophosphamide-doxorubicin-polatuzumab vedotin -prednisolone – rituximab Indication • Previously untreated diffuse
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/PV-CHP-Cyclophosphamide-doxorubicin-polatuzumab-vedotin-prednisolone.pdf
591 to 600 of 630
Previous … 58 59 60 61 62 … Next